Bruce Gillis, M.D., M.P.H., medical toxicologist and CEO of The Cytokine Institute research group, recently presented a tutorial on new genomics-based technology called msds1and how it will impact workers' compensation claims at the International Congress of Toxicology in Montreal.

The technology analyzes gene expression and how 36,000 parameters of an individual's DNA are affected by exposure to chemicals, such as benzene or asbestos. Msds1 can determine with 99.9 percent certainty if a person was exposed to dangerous levels of a particular toxin, providing an impartial methodology for producing scientifically-based evidence to help reduce fraudulent claims.

Dr. Gillis will also discuss the technology's potential ramifications on the fields of healthcare, insurance, and mass-tort litigation.

Recommended For You

Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader

Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
  • Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
NOT FOR REPRINT

© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more inforrmation visit Asset & Logo Licensing.